Regulation and involvement of matrix metalloproteinases in vascular diseases (original) (raw)

• [1] J. Gross and C. M. Lapiere: Collagenolytic activity in amphibian tissues: a tissue culture assay. Proc Natl Acad Sci U S A, 48, 1014-22 (1962)
• [2] K. Maskos: Crystal structures of MMPs in complex with physiological and pharmacological inhibitors. Biochimie, 87(3-4), 249-263 (2005)
• [3] M. S. Razzaque, S. Kumari, C. S. Foster and A. R. Ahmed: Expression profiles of collagens, HSP47, TGF-beta1, MMPs and TIMPs in epidermolysis bullosa acquisita. Cytokine, 21(5), 207-13 (2003)
• [4] I. K. Demedts, A. Morel-Montero, S. Lebecque, Y. Pacheco, D. Cataldo, G. F. Joos, R. A. Pauwels and G. G. Brusselle: Elevated MMP-12 protein levels in induced sputum from patients with COPD. Thorax, 61(3), 196-201 (2006)
• [5] B. Lovejoy, A. Cleasby, A. M. Hassell, K. Longley, M. A. Luther, D. Weigl, G. McGeehan, A. B. McElroy, D. Drewry, M. H. Lambert and et al.: Structure of the catalytic domain of fibroblast collagenase complexed with an inhibitor. Science, 263(5145), 375-7 (1994)
• [6] I. Massova, L. P. Kotra, R. Fridman and S. Mobashery: Matrix metalloproteinases: structures, evolution, and diversification. FASEB J, 12(12), 1075-95 (1998)
• [7] C. M. Overall: Molecular determinants of metalloproteinase substrate specificity: matrix metalloproteinase substrate binding domains, modules, and exosites. Mol Biotechnol, 22(1), 51-86 (2002)
• [8] J. D. Raffetto and R. A. Khalil: Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochem Pharmacol, 75(2), 346-59 (2008)
• [9] J. Bujan, F. Jurado, M. J. Gimeno, N. Garcia-Honduvilla, G. Pascual, J. Jimenez and J. M. Bellon: Changes in metalloproteinase (MMP-1, MMP-2) expression in the proximal region of the varicose saphenous vein wall in young subjects. Phlebology, 15(2), 64-70 (2000)
• [10] A. C. Newby: Matrix metalloproteinases regulate migration, proliferation, and death of vascular smooth muscle cells by degrading matrix and non-matrix substrates. Cardiovasc Res, 69(3), 614-24 (2006)
• [11] M. Back, D. F. Ketelhuth and S. Agewall: Matrix metalloproteinases in atherothrombosis. Prog Cardiovasc Dis, 52(5), 410-28 (2010)
• [12] T. Alsaigh, E. S. Pocock, J. J. Bergan and G. W. Schmid-Schonbein: Acute venous occlusion enhances matrix metalloprotease activity: Implications on endothelial dysfunction. Microvasc Res, 81(1), 108-16 (2011)
• [13] F. A. DeLano and G. W. Schmid-Schonbein: Proteinase activity and receptor cleavage: mechanism for insulin resistance in the spontaneously hypertensive rat. Hypertension, 52(2), 415-23 (2008)
• [14] P. Clancy, S. W. Seto, S. A. Koblar and J. Golledge: Role of the angiotensin converting enzyme 1/angiotensin II/angiotensin receptor 1 axis in interstitial collagenase expression in human carotid atheroma. Atherosclerosis, 229(2), 331-7 (2013)
• [15] B. Lavin, M. Gomez, O. M. Pello, B. Castejon, M. J. Piedras, M. Saura and C. Zaragoza: Nitric Oxide Prevents Aortic Neointimal Hyperplasia by Controlling Macrophage Polarization. Arterioscler Thromb Vasc Biol (2014)
• [16] K. M. Austin, L. Covic and A. Kuliopulos: Matrix metalloproteases and PAR1 activation. Blood, 121(3), 431-9 (2013)
• [17] A. K. Ahmed, J. L. Haylor, A. M. El Nahas and T. S. Johnson: Localization of matrix metalloproteinases and their inhibitors in experimental progressive kidney scarring. Kidney Int, 71(8), 755-763 (2007)
• [18] O. Lenz, S. J. Elliot and W. G. Stetler-Stevenson: Matrix metalloproteinases in renal development and disease. J Am Soc Nephrol, 11(3), 574-81 (2000)
• [19] U. Sen, P. B. Sathnur, S. Kundu, S. Givvimani, D. M. Coley, P. K. Mishra, N. Qipshidze, N. Tyagi, N. Metreveli and S. C. Tyagi: Increased endogenous H2S generation by CBS, CSE, and 3MST gene therapy improves ex vivo renovascular relaxation in hyperhomocysteinemia. Am J Physiol Cell Physiol, 303(1), C41-51 (2012)
• [20] T. Quillard, Y. Tesmenitsky, K. Croce, R. Travers, E. Shvartz, K. C. Koskinas, G. K. Sukhova, E. Aikawa, M. Aikawa and P. Libby: Selective inhibition of matrix metalloproteinase-13 increases collagen content of established mouse atherosclerosis. Arterioscler Thromb Vasc Biol, 31(11), 2464-72 (2011)
• [21] G. M. Grant, T. A. Giambernardi, A. M. Grant and R. J. Klebe: Overview of expression of matrix metalloproteinases (MMP-17, MMP-18, and MMP-20) in cultured human cells. Matrix Biol, 18(2), 145-148 (1999)
• [22] M. J. Foos, J. R. Hickox, P. G. Mansour, J. R. Slauterbeck and D. M. Hardy: Expression of matrix metalloprotease and tissue inhibitor of metalloprotease genes in human anterior cruciate ligament. J Ortho Res, 19(4), 642-649 (2001)
• [23] S. Kaptoge, S. R. K. Seshasai, P. Gao, D. F. Freitag, A. S. Butterworth, A. Borglykke, E. Di Angelantonio, V. Gudnason, A. Rumley, G. D. O. Lowe, T. Jorgensen and J. Danesh: Inflammatory cytokines and risk of coronary heart disease: new prospective study and updated meta-analysis. Eur Heart J, 35(9), 578-U35 (2014)
• [24] S. Lenglet, A. Quercioli, M. Fabre, K. Galan, G. Pelli, A. Nencioni, I. Bauer, A. Pende, M. Python, M. Bertolotto, G. Spinella, B. Pane, D. Palombo, F. Dallegri, F. Mach, N. Vuilleumier and F. Montecucco: Statin Treatment Is Associated with Reduction in Serum Levels of Receptor Activator of NF-kappa B Ligand and Neutrophil Activation in Patients with Severe Carotid Stenosis. Mediators Inflamm (2014)
• [25] E. Scoditti, A. Nestola, M. Massaro, N. Calabriso, C. Storelli, R. De Caterina and M. A. Carluccio: Hydroxytyrosol suppresses MMP-9 and COX-2 activity and expression in activated human monocytes via PKC alpha and PKC beta 1 inhibition. Atherosclerosis, 232(1), 17-24 (2014)
• [26] C. H. Tan, Y. Liu, W. N. Li, F. Deng, X. Liu, X. Wang, Y. J. Gui, L. Qin, C. L. Hu and L. F. Chen: Associations of matrix metalloproteinase-9 and monocyte chemoattractant protein-1 concentrations with carotid atherosclerosis, based on measurements of plaque and intima-media thickness. Atherosclerosis, 232(1), 199-203 (2014)
• [27] D. Palmieri, P. Perego and D. Palombo: Estrogen Receptor Activation Protects Against TNF-alpha-Induced Endothelial Dysfunction. Angiology, 65(1), 17-21 (2014)
• [28] L. Sun, S. Chandra and P. Sucosky: Ex vivo evidence for the contribution of hemodynamic shear stress abnormalities to the early pathogenesis of calcific bicuspid aortic valve disease. PLoS One, 7(10), e48843 (2012)
• [29] S. T. Gould, S. Srigunapalan, C. A. Simmons and K. S. Anseth: Hemodynamic and cellular response feedback in calcific aortic valve disease. Circ Res, 113(2), 186-97 (2013)
• [30] L. Sun, N. M. Rajamannan and P. Sucosky: Defining the Role of Fluid Shear Stress in the Expression of Early Signaling Markers for Calcific Aortic Valve Disease. PLoS One, 8(12) (2013)
• [31] L. B. Khzam, R. Boulahya, H. Abou-Saleh, A. Hachem, Y. Zaid and Y. Merhi: Soluble CD40 Ligand Stimulates the Pro-Angiogenic Function of Peripheral Blood Angiogenic Outgrowth Cells via Increased Release of Matrix Metalloproteinase-9. PLoS One, 8(12) (2013)
• [32] H. Kim, S. Bae, Y. Kim, C. H. Cho, S. J. Kim, Y. J. Kim, S. P. Lee, H. R. Kim, Y. I. Hwang, J. S. Kang and W. J. Lee: Vitamin C prevents stress-induced damage on the heart caused by the death of cardiomyocytes, through down-regulation of the excessive production of catecholamine, TNF-alpha, and ROS production in Gulo (-/-)(Vit C-Insufficient) mice. Free Radic Biol Med, 65, 573-583 (2013)
• [33] P. K. Mishra, S. Givvimani, V. Chavali and S. C. Tyagi: Cardiac matrix: A clue for future therapy. Biochim Biophys Acta 1832(12), 2271-2276 (2013)
• [34] A. L. Jacob-Ferreira and R. Schulz: Activation of intracellular matrix metalloproteinase-2 by reactive oxygen nitrogen species: Consequences and therapeutic strategies in the heart. Arch Biochem Biophys, 540(1-2), 82-93 (2013)
• [35] J. D. Raffetto, R. L. Ross and R. A. Khalil: Matrix metalloproteinase 2-induced venous dilation via hyperpolarization and activation of K+ channels: relevance to varicose vein formation. J Vasc Surg, 45(2), 373-80 (2007)
• [36] S. B. Jeon, S. Chun, S. Choi-Kwon, H. S. Chi, H. W. Nah, S. U. Kwon, W. K. Kim and J. S. Kim: Biomarkers and location of atherosclerosis: Matrix metalloproteinase-2 may be related to intracranial atherosclerosis. Atherosclerosis, 223(2), 442-447 (2012)
• [37] K. Shimizu, K. Shimomura, Y. Tokuyama, K. Sakurai, K. Isahaya, S. Takaishi, B. Kato, N. Usuki, T. Shimizu, K. Yamada and Y. Hasegawa: Association between Inflammatory Biomarkers and Progression of Intracranial Large Artery Stenosis after Ischemic Stroke. J Stroke Cerebrovasc Dis, 22(3), 211-217 (2013)
• [38] S. H. Heo, C. H. Cho, H. O. Kim, Y. H. Jo, K. S. Yoon, J. H. Lee, J. C. Park, K. C. Park, T. B. Ahn, K. C. Chung, S. S. Yoon and D. I. Chang: Plaque Rupture is a Determinant of Vascular Events in Carotid Artery Atherosclerotic Disease: Involvement of Matrix Metalloproteinases 2 and 9. J Clin Neurol, 7(2), 69-76 (2011)
• [39] S. Givvimani, S. Kundu, N. Narayanan, F. Armaghan, N. Qipshidze, S. Pushpakumar, T. P. Vacek and S. C. Tyagi: TIMP-2 mutant decreases MMP-2 activity and augments pressure overload induced LV dysfunction and heart failure. Arch Physiol Biochem, 119(2), 65-74 (2013)
• [40] P. Shivshankar, C. Brampton, S. Miyasato, M. Kasper, V. J. Thannickal and C. J. Le Saux: Caveolin-1 Deficiency Protects from Pulmonary Fibrosis by Modulating Epithelial Cell Senescence in Mice. Am J Respir Cell Mol Biol, 47(1), 28-36 (2012)
• [41] Y. Gu, G. Q. Zheng, M. J. Xu, Y. Li, X. M. Chen, W. Z. Zhu, Y. Tong, S. K. Chung, K. J. Liu and J. G. Shen: Caveolin-1 regulates nitric oxide-mediated matrix metalloproteinases activity and blood-brain barrier permeability in focal cerebral ischemia and reperfusion injury. J Neurochem, 120(1), 147-156 (2012)
• [42] N. Muradashvili, R. Tyagi, N. Metreveli, S. C. Tyagi and D. Lominadze: Ablation of MMP9 gene ameliorates paracellular permeability and fibrinogen-amyloid beta complex formation during hyperhomocysteinemia. J Cereb Blood Flow Metab, 34(9), 1472-82 (2014)
• [43] N. Muradashvili, R. L. Benton, K. E. Saatman, S. C. Tyagi and D. Lominadze: Ablation of matrix metalloproteinase-9 gene decreases cerebrovascular permeability and fibrinogen deposition post traumatic brain injury in mice. Metab Brain Dis (2014)
• [44] P. Giuffrida, P. Biancheri and T. T. MacDonald: Proteases and small intestinal barrier function in health and disease. Curr Opin Gastroenterol, 30(2), 147-53 (2014)
• [45] P. SanSilvestri-Morel, F. Fioretti, A. Rupin, K. Senni, J. N. Fabiani, G. Godeau and T. J. Verbeuren: Comparison of extracellular matrix in skin and saphenous veins from patients with varicose veins: does the skin reflect venous matrix changes? Clinical Science, 112(3-4), 229-239 (2007)
• [46] G. Zhang, M. Miyake, A. Lawton, S. Goodison and C. J. Rosser: Matrix metalloproteinase-10 promotes tumor progression through regulation of angiogenic and apoptotic pathways in cervical tumors. BMC Cancer, 14(1), 310 (2014)
• [47] B. J. Boucher: Matrix metalloproteinase-10 and microvascular complications of type 1 diabetes: might vitamin D status be relevant? Diabetologia, 57(5), 1081-1081 (2014)
• [48] M. Bobadilla, N. Sainz, J. A. Rodriguez, G. Abizanda, J. Orbe, A. de Martino, J. M. G. Verdugo, J. A. Paramo, F. Prosper and A. Perez-Ruiz: MMP-10 Is Required for Efficient Muscle Regeneration in Mouse Models of Injury and Muscular Dystrophy. Stem Cells, 32(2), 447-461 (2014)
• [49] J. Tan, E. Buache, F. Alpy, E. Daguenet, C. L. Tomasetto, G. S. Ren and M. C. Rio: Stromal matrix metalloproteinase-11 is involved in the mammary gland postnatal development. Oncogene, 33(31), 4050-59 (2013)
• [50] E. R. Motrescu, S. Blaise, N. Etique, N. Messaddeq, M. P. Chenard, I. Stoll, C. Tomasetto and M. C. Rio: Matrix metalloproteinase-11/stromelysin-3 exhibits collagenolytic function against collagen VI under normal and malignant conditions. Oncogene, 27(49), 6347-55 (2008)
• [51] H. Sato, T. Takino, Y. Okada, J. Cao, A. Shinagawa, E. Yamamoto and M. Seiki: A Matrix Metalloproteinase Expressed on the Surface of Invasive Tumor-Cells. Nature, 370(6484), 61-65 (1994)
• [52] I. Anik, S. Kokturk, H. Genc, B. Cabuk, K. Koc, S. Yavuz, S. Ceylan, S. Ceylan, L. Kamaci and Y. Anik: Immunohistochemical analysis of TIMP-2 and collagen types I and IV in experimental spinal cord ischemia-reperfusion injury in rats. J Spin Cord Med, 34(3), 257-264 (2011)
• [53] E. Candelario-Jalil, Y. Yang and G. A. Rosenberg: Diverse Roles of Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Neuroinflammation and Cerebral Ischemia. Neuroscience, 158(3), 983-994 (2009)
• [54] J. A. Thompson, B. S. Richardson, R. Gagnon and T. R. H. Regnault: Chronic intrauterine hypoxia interferes with aortic development in the late gestation ovine fetus. J Physio-London, 589(13), 3319-3332 (2011)
• [55] R. Yang, H. Liu, I. Williams and B. Chaqour: Matrix metalloproteinase-2 expression and apoptogenic activity in retinal pericytes: implications in diabetic retinopathy. Ann N Y Acad Sci, 1103, 196-201 (2007)
• [56] J. H. Park, S. M. Park, S. H. Park, K. H. Cho and S. T. Lee: Cleavage and functional loss of human apolipoprotein E by digestion of matrix metalloproteinase-14. Proteomics, 8(14), 2926-2935 (2008)
• [57] J. H. Park, S. M. Park, K. H. Park, K. H. Cho and S. T. Lee: Analysis of apolipoprotein A-I as a substrate for matrix metalloproteinase-14. Biochem Biophys Res Comm, 409(1), 58-63 (2011)
• [58] T. Waldow, W. Witt, A. Buzin, A. Ulmer and K. Matschke: Prevention of ischemia/reperfusion-induced accumulation of matrix metalloproteinases in rat lung by preconditioning with nitric oxide. J Surg Res, 152(2), 198-208 (2009)
• [59] J. Lin, H. B. Davis, Q. X. Dai, Y. M. Chou, T. Craig, C. Hinojosa-Laborde and M. L. Lindsey: Effects of early and late chronic pressure overload on extracellular matrix remodeling. Hypertens Res, 31(6), 1225-1231 (2008)
• [60] K. Straat, R. de Klark, S. Gredmark-Russ, P. Eriksson and C. Soderberg-Naucler: Infection with Human Cytomegalovirus Alters the MMP-9/TIMP-1 Balance in Human Macrophages. J Virol, 83(2), 830-835 (2009)
• [61] M. Feng, X. J. Cai, W. Zhang, X. L. Liu, L. Chen, Y. Zhang, M. X. Zhang and M. Zhang: Interleukin-6 enhances matrix metalloproteinase-14 expression via the RAF-mitogen-activated protein kinase kinase-extracellular signal-regulated kinase 1/2-activator protein-1 pathway. Clin Exp Pharmacol Physiol, 37(2), 162-166 (2010)
• [62] M. Zack, B. B. Boyanovsky, P. Shridas, W. Bailey, K. Forrest, D. A. Howatt, M. H. Gelb, F. C. de Beer, A. Daugherty and N. R. Webb: Group X secretory phospholipase A(2) augments angiotensin II-induced inflammatory responses and abdominal aortic aneurysm formation in apoE-deficient mice. Atherosclerosis, 214(1), 58-64 (2011)
• [63] V. Sood, C. E. Luke, K. B. Deatrick, J. Baldwin, E. M. Miller, M. Elfline, G. R. Upchurch, T. W. Wakefield and P. K. Henke: Urokinase plasminogen activator independent early experimental thrombus resolution: MMP2 as an alternative mechanism. Thromb Haemost, 104(6), 1174-1183 (2010)
• [64] M. Pons, S. W. Cousins, O. Alcazar, G. E. Striker and M. E. Marin-Castano: Angiotensin II-induced MMP-2 activity and MMP-14 and basigin protein expression are mediated via the angiotensin II receptor type 1-mitogen-activated protein kinase 1 pathway in retinal pigment epithelium: implications for age-related macular degeneration. Am J Pathol, 178(6), 2665-81 (2011)
• [65] S. M. Cork, B. Kaur, N. S. Devi, L. Cooper, J. H. Saltz, E. M. Sandberg, S. Kaluz and E. G. Van Meir: A proprotein convertase/MMP-14 proteolytic cascade releases a novel 40 kDa vasculostatin from tumor suppressor BAI1. Oncogene, 31(50), 5144-52 (2012)
• [66] C. S. Ceron, E. Rizzi, D. A. Guimaraes, A. Martins-Oliveira, S. B. Cau, J. Ramos, R. F. Gerlach and J. E. Tanus-Santos: Time course involvement of matrix metalloproteinases in the vascular alterations of renovascular hypertension. Matrix Biol, 31(4), 261-70 (2012)
• [67] S. Duarte, X. D. Shen, C. Fondevila, R. W. Busuttil and A. J. Coito: Fibronectin-alpha4beta1 interactions in hepatic cold ischemia and reperfusion injury: regulation of MMP-9 and MT1-MMP via the p38 MAPK pathway. Am J Transplant, 12(10), 2689-99 (2012)
• [68] A. Radziwon-Balicka, C. Ramer, C. Moncada de la Rosa, B. Zielnik-Drabik and P. Jurasz: Angiostatin inhibits endothelial MMP-2 and MMP-14 expression: a hypoxia specific mechanism of action. Vascul Pharmacol, 58(4), 280-91 (2013)
• [69] J. Xu, Y. Sun, T. Wang and G. Liu: Prevention of neointimal hyperplasia in balloon-injured rat carotid artery via small interference RNA mediated downregulation of osteopontin gene. Mol Cell Biochem, 377(1-2), 1-10 (2013)
• [70] X. S. Vasko R, Chen J, Lin CH, Ratliff B, Rabadi M, Maizel J, Tanokuchi R, Zhang F, Cao J, Goligorsky MS.: Endothelial sirtuin 1 deficiency perpetrates nephrosclerosis through downregulation of matrix metalloproteinase-14: relevance to fibrosis of vascular senescence. J Am Soc Nephrol, 25(2), 276-91 (2014)
• [71] Y. N. Fu, J. A. Nagy, L. F. Brown, S. C. Shih, P. Y. Johnson, C. K. Chan, H. F. Dvorak and T. N. Wight: Proteolytic Cleavage of Versican and Involvement of ADAMTS-1 in VEGF-A/VPF-Induced Pathological Angiogenesis. J Histochem Cytochem, 59(5), 463-473 (2011)
• [72] S. K. Shin JI, Kim H, Cho NH, Kim J, Kim HS, Lee JS: The gene expression profile of matrix metalloproteinases and their inhibitors in children with Henoch-Schönlein purpura. Br J Dermatol, 164(2), 1348-55 (2011)
• [73] Y. B. Zhang, W. Li, L. Q. Yao, X. L. Zhao, B. Wang, H. K. Li, Y. Ning, E. Song and X. X. Zhang: Expression changes and roles of matrix metalloproteinases in a rat model of traumatic deep vein thrombosis. Chin J Traumatol, 13(3), 188-92 (2010)
• [74] L. Host, A. Paye, B. Detry, S. Blacher, C. Munaut, J. M. Foidart, M. Seiki, N. E. Sounni and A. Noel: The proteolytic activity of MT4-MMP is required for its pro-angiogenic and pro-metastatic promoting effects. Int J Canc, 131(7), 1537-1548 (2012)
• [75] H. Abdul-Hussien, R. Hanemaaijer, J. H. Verheijen, J. H. van Bockel, R. H. Geelkerken and J. H. N. Lindeman: Doxycycline therapy for abdominal aneurysm: Improved proteolytic balance through reduced neutrophil content. J Vasc Surg, 49(3), 741-749 (2009)
• [76] S.-N. G. Huang WC, Susana A, Johnson JL, Newby AC.: Classical macrophage activation up-regulates several matrix metalloproteinases through mitogen activated protein kinases and nuclear factor-κB. PLoS One, 7(8)(2012)
• [77] Y. A. Chiao, R. Zamilpa, E. F. Lopez, Q. X. Dai, G. P. Escobar, K. Hakala, S. T. Weintraub and M. L. Lindsey: In vivo Matrix Metalloproteinase-7 Substrates Identified in the Left Ventricle Post-Myocardial Infarction Using Proteomics. J Proteome Res, 9(5), 2649-2657 (2010)
• [78] A. Yabluchanskiy, Y. Li, L. E. de Castro Bras, K. Hakala, S. T. Weintraub and M. L. Lindsey: Proteomic analysis of the left ventricle post-myocardial infarction to identify in vivo candidate matrix metalloproteinase substrates. Methods Mol Biol, 1066, 185-99 (2013)
• [79] H. L. Su K, Li W, Yan X, Li X, Zhang Z, Jin F, Lei J, Ba G, Liu B, Wang X, Wang Y.: TC-1 (c8orf4) enhances aggressive biologic behavior in lung cancer through the Wnt/β-catenin pathway. J Surg Res, 185(1), 255-63 (2012)
• [80] R. Reindel, S. C. Baker, K. Y. Kim, C. A. Rowley, S. T. Shulman, J. M. Orenstein, E. J. Perlman, M. W. Lingen and A. H. Rowley: Integrins alpha4 and alphaM, collagen1A1, and matrix metalloproteinase 7 are upregulated in acute Kawasaki disease vasculopathy. Pediatr Res, 73(3), 332-6 (2013)
• [81] W. A. LaFramboise, R. Dhir, L. A. Kelly, P. Petrosko, J. M. Krill-Burger, C. M. Sciulli, M. A. Lyons-Weiler, U. R. Chandran, A. Lomakin, R. V. Masterson, O. C. Marroquin, S. R. Mulukutla and D. M. McNamara: Serum protein profiles predict coronary artery disease in symptomatic patients referred for coronary angiography. BMC Med, 10, 157 (2012)
• [82] A. Razuvaev, J. Ekstrand, L. Folkersen, H. Agardh, D. Markus, J. Swedenborg, G. K. Hansson, A. Gabrielsen, G. Paulsson-Berne, J. Roy and U. Hedin: Correlations Between Clinical Variables and Gene-expression Profiles in Carotid Plaque Instability. Eur J Vasc Endovasc Surg, 42(6), 722-730 (2011)
• [83] S. Tong, H. J. Neboori, E. D. Tran and G. W. Schmid-Schonbein: Constitutive Expression and Enzymatic Cleavage of ICAM-1 in the Spontaneously Hypertensive Rat. J Vasc Res, 48(5), 386-396 (2011)
• [84] P. Chieng-Yane, A. Bocquet, R. Letienne, T. Bourbon, S. Sablayrolles, M. Perez, S. N. Hatem, A. M. Lompre, B. Le Grand and M. David-Dufilho: Protease-activated receptor-1 antagonist F 16618 reduces arterial restenosis by down-regulation of tumor necrosis factor alpha and matrix metalloproteinase 7 expression, migration, and proliferation of vascular smooth muscle cells_. J Pharmacol Exp Ther_, 336(3), 643-51 (2011)
• [85] J. Odenbach, X. Wang, S. Cooper, F. L. Chow, T. Oka, G. Lopaschuk, Z. Kassiri and C. Fernandez-Patron: MMP-2 mediates angiotensin II-induced hypertension under the transcriptional control of MMP-7 and TACE. Hypertension, 57(1), 123-30 (2011)
• [86] P. M. Vanhoutte: Regeneration of the endothelium in vascular injury. Cardiovasc Drugs Ther, 24(4), 299-303 (2010)
• [87] S. F. Rodrigues, E. D. Tran, Z. B. Fortes and G. W. Schmid-Schonbein: Matrix metalloproteinases cleave the beta2-adrenergic receptor in spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol, 299(1), H25-35 (2010)
• [88] E. Pirila, J. T. Korpi, T. Korkiamaki, T. Jahkola, A. Gutierrez-Fernandez, C. Lopez-Otin, U. Saarialho-Kere, T. Salo and T. Sorsa: Collagenase-2 (MMP-8) and matrilysin-2 (MMP-26) expression in human wounds of different etiologies. Wound Repair Regen, 15(1), 47-57 (2007)
• [89] A. S. Krishnatry, D. A. Brazeau and H. L. Fung: Broad regulation of matrix and adhesion molecules in THP-1 human macrophages by nitroglycerin. Nitric Oxide, 22(1), 11-7 (2010)
• [90] M. Tanskanen, L. Myllykangas, U. Saarialho-Kere and A. Paetau: Matrix metalloproteinase-beta19 expressed in cerebral amyloid angiopathy. Amyloid, 18(1), 3-9 (2011)
• [91] S. D. Shapiro, D. K. Kobayashi and T. J. Ley: Cloning and characterization of a unique elastolytic metalloproteinase produced by human alveolar macrophages. J Biol Chem, 268(32), 23824-9 (1993)
• [92] J. L. Johnson, L. Devel, B. Czarny, S. J. George, C. L. Jackson, V. Rogakos, F. Beau, A. Yiotakis, A. C. Newby and V. Dive: A selective matrix metalloproteinase-12 inhibitor retards atherosclerotic plaque development in apolipoprotein E-knockout mice. Arterioscler Thromb Vasc Biol, 31(3), 528-35 (2011)
• [93] W. Jithpratuck, Y. Elshenawy, H. Saleh, G. Youngberg, D. S. Chi and G. Krishnaswamy: The clinical implications of adult-onset henoch-schonelin purpura. Clin Mol Allergy, 9(1), 9 (2011)
• [94] M. Proietta, L. Tritapepe, N. Cifani, L. Ferri, M. Taurino and F. Del Porto: MMP-12 as a new marker of Stanford-A acute aortic dissection. Ann Med, 46(1), 44-48 (2014)
• [95] K. T. Ji, Y. Zhang, F. C. Jiang, L. Qian, H. H. Guo, J. J. Hu, L. M. Liao and J. F. Tang: Exploration of the mechanisms by which 3,4-benzopyrene promotes angiotensin II-induced abdominal aortic aneurysm formation in mice. J Vasc Surg, 59(2), 492-499 (2014)
• [96] Y. Song, Y. H. Xie, F. Liu, C. Zhao, R. Yu, S. Ban, Q. F. Ye, J. X. Wen, H. B. Wan, X. Li, R. W. Ma and Z. H. Meng: Expression of matrix metalloproteinase-12 in aortic dissection. BMC Cardiovasc Disord, 13 (2013)
• [97] M. Tao, P. Yu, B. T. Nguyen, B. Mizrahi, N. Savion, F. D. Kolodgie, R. Virmani, S. Hao, C. K. Ozaki and J. Schneiderman: Locally Applied Leptin Induces Regional Aortic Wall Degeneration Preceding Aneurysm Formation in Apolipoprotein E-Deficient Mice. Arterioscler Thromb Vasc Biol, 33(2), 311 (2013)
• [98] T. Wolak, N. Sion-Vardi, V. Novack, G. Greenberg, G. Szendro, T. Tarnovscki, O. Nov, I. Shelef, E. Paran and A. Rudich: N-Terminal Rather Than Full-Length Osteopontin or Its C-Terminal Fragment Is Associated With Carotid-Plaque Inflammation in Hypertensive Patients. Am J Hypertens, 26(3), 326-333 (2013)
• [99] V. P. W. Scholtes, J. L. Johnson, N. Jenkins, G. B. Sala-Newby, J. P. P. M. de Vries, G. J. de Borst, D. P. V. de Kleijn, F. L. Moll, G. Pasterkamp and A. C. Newby: Carotid Atherosclerotic Plaque Matrix Metalloproteinase-12-Positive Macrophage Subpopulation Predicts Adverse Outcome After Endarterectomy. J Am Heart Assoc, 1(6)(2012)
• [100] R. M. Korol, P. B. Canham, L. Liu, K. Viswanathan, G. G. Ferguson, R. R. Hammond, H. M. Finlay, H. V. Baker, C. Lopez and A. R. Lucas: Detection of Altered Extracellular Matrix in Surface Layers of Unstable Carotid Plaque: An Optical Spectroscopy, Birefringence and Microarray Genetic Analysis. Photochem Photobiol, 87(5), 1164-1172 (2011)
• [101] J. M. Li, J. J. Wang, Q. S. Peng, C. Chen, M. B. Humphrey, J. Heinecke and S. X. Zhang: Macrophage Metalloelastase (MMP-12) Deficiency Mitigates Retinal Inflammation and Pathological Angiogenesis in Ischemic Retinopathy. PLoS One, 7(12) (2012)
• [102] J. W. Shin, H. C. Kang, J. Shim and N. W. Sohn: Scutellaria baicalensis Attenuates Blood-Brain Barrier Disruption after Intracerebral Hemorrhage in Rats. Am J Chin Med, 40(1), 85-96 (2012)
• [103] P. Svedin, H. Hagberg and C. Mallard: Expression of MMP-12 after Neonatal Hypoxic-Ischemic Brain Injury in Mice. Dev Neurosci, 31(5), 427-436 (2009)
• [104] M. Manetti, S. Guiducci, E. Romano, S. Bellando-Randone, M. L. Conforti, L. Ibba-Manneschi and M. Matucci-Cerinic: Increased serum levels and tissue expression of matrix metalloproteinase-12 in patients with systemic sclerosis: correlation with severity of skin and pulmonary fibrosis and vascular damage. Ann Rheum Dis, 71(6), 1064-1072 (2012)
• [105] J. S. Ikonomidis, J. M. Ruddy, S. M. Benton, J. Arroyo, T. A. Brinsa, R. E. Stroud, A. Zeeshan, J. E. Bavaria, J. H. Gorman, R. C. Gorman, F. G. Spinale and J. A. Jones: Aortic Dilatation With Bicuspid Aortic Valves: Cusp Fusion Correlates to Matrix Metalloproteinases and Inhibitors INVITED COMMENTARY. Ann Thorac Surg, 93(2), 457-464 (2012)
• [106] J. Ryan, F. Y. Ma, J. Kanellis, M. Delgado, K. Blease and D. J. Nikolic-Paterson: Spleen tyrosine kinase promotes acute neutrophil-mediated glomerular injury via activation of JNK and p38 MAPK in rat nephrotoxic serum nephritis. Lab Invest, 91(12), 1727-1738 (2011)
• [107] C. Shimizu, T. Matsubara, Y. Onouchi, S. Jain, S. Sun, C. M. Nievergelt, H. Shike, V. H. Brophy, T. Takegawa, S. Furukawa, T. Akagi, J. W. Newburger, A. L. Baker, D. Burgner, M. L. Hibberd, S. Davila, M. Levin, M. Mamtani, W. J. He, S. K. Ahuja and J. C. Burns: Matrix metalloproteinase haplotypes associated with coronary artery aneurysm formation in patients with Kawasaki disease. J Hum Genet, 55(12), 779-784 (2010)
• [108] G. Arunachalam, I. K. Sundar, J. W. Hwang, H. W. Yao and I. Rahman: Emphysema is associated with increased inflammation in lungs of atherosclerosis-prone mice by cigarette smoke: implications in comorbidities of COPD. J Inflamm-London, 7 (2010)
• [109] N. S. Pauwels, K. R. Bracke, T. Maes, G. R. Van Pottelberge, C. Garlanda, A. Mantovani, G. F. Joos and G. G. Brusselle: Cigarette smoke induces PTX3 expression in pulmonary veins of mice in an IL-1 dependent manner. Respir Res, 11 (2010)
• [110] V. Jackson, T. Olsson, S. Kurtovic, L. Folkersen, V. Paloschi, D. Wagsater, A. Franco-Cereceda and P. Eriksson: Matrix metalloproteinase 14 and 19 expression is associated with thoracic aortic aneurysms. J Thorac Cardiovasc Surg, 144(2), 459-466 (2012)
• [111] W. A. Roscoe, M. E. Welsh, D. E. Carter and S. J. Karlik: VEGF and angiogenesis in acute and chronic MOG((35-55)) peptide induced EAE. J Neuroimmunol, 209(1-2), 6-15 (2009)
• [112] M. S. Kolb C, Krawinkel U, Sedlacek R.: Matrix metalloproteinase-19 in capillary endothelial cells: expression in acutely, but not in chronically, inflamed synovium. Exp Cell Res, 250(1), 122-30 (1999)
• [113] L. Hegedus, H. Cho, X. Xie and G. L. Eliceiri: Additional MDA-MB-231 breast cancer cell matrix metalloproteinases promote invasiveness. J Cell Physiol, 216(2), 480-5 (2008)
• [114] K. Ahokas, J. Lohi, H. Lohi, O. Elomaa, M. L. Karjalainen-Lindsberg, J. Kere and U. Saarialho-Kere: Matrix metalloproteinase-21, the human orthologue for XMMP, is expressed during fetal development and in cancer. Gene, 301(1-2), 31-41 (2002)
• [115] T. Kuivanen, K. Ahokas, S. Virolainen, T. Jahkola, E. Holtta, O. Saksela and U. Saarialho-Kere: MMP-21 is upregulated at early stages of melanoma progression but disappears with more aggressive phenotype. Virchows Archiv, 447(6), 954-960 (2005)
• [116] T. Skoog, O. Elomaa, S. M. Pasonen-Seppanen, S. Forsberg, K. Ahokas, L. Jeskanen, J. Parssinen, I. Tiala, O. Rollman, J. Lohi and U. Saarialho-Kere: Matrix Metalloproteinase-21 Expression Is Associated with Keratinocyte Differentiation and Upregulated by Retinoic Acid in HaCaT Cells. J Invest Dermatol, 129(1), 119-130 (2009)
• [117] G. N. Marchenko, N. D. Marchenko and A. Y. Strongin: The structure and regulation of the human and mouse matrix metalloproteinase-21 gene and protein. Biochem J, 372(Pt 2), 503-15 (2003)
• [118] Y. Huang, W. H. Li, D. K. Chu, J. Y. Zheng, G. Ji, M. B. Li, H. W. Zhang, W. Z. Wang, J. J. Du and J. P. Li: Overexpression of Matrix Metalloproteinase-21 is Associated with Poor Overall Survival of Patients with Colorectal Cancer. J Gastrointest Surg, 15(7), 1188-1194 (2011)
• [119] T. Wu, Y. Li, J. G. Lu, Q. Qiao, G. Q. Bao, N. Wang, X. L. He and X. L. Du: Increased MMP-21 expression is associated with poor overall survival of patients with gastric cancer. Med Oncol, 30(1) (2013)
• [120] R. Gururajan, J. Grenet, J. M. Lahti and V. J. Kidd: Isolation and characterization of two novel metalloproteinase genes linked to the Cdc2L locus on human chromosome 1p36.3. Genomics, 52(1), 101-6 (1998)
• [121] M. Gajecka, W. Yu, B. C. Ballif, C. D. Glotzbach, K. A. Bailey, C. A. Shaw, C. D. Kashork, H. A. Heilstedt, D. A. Ansel, A. Theisen, R. Rice, D. P. Rice and L. G. Shaffer: Delineation of mechanisms and regions of dosage imbalance in complex rearrangements of 1p36 leads to a putative gene for regulation of cranial suture closure. Eur J Hum Genet, 13(2), 139-49 (2005)
• [122] J. Lohi, C. L. Wilson, J. D. Roby and W. C. Parks: Epilysin, a novel human matrix metalloproteinase (MMP-28) expressed in testis and keratinocytes and in response to injury. J Biol Chem, 276(13), 10134-10144 (2001)
• [123] F. Bernal, H. P. Hartung and B. C. Kieseier: Tissue mRNA expression in rat of newly described matrix metalloproteinases. Biol Res, 38(2-3), 267-271 (2005)
• [124] A. K. Murugan, C. F. Yang and M. Z. Xing: Mutational analysis of the GNA11, MMP27, FGD1, TRRAP and GRM3 genes in thyroid cancer. Oncol Lett, 6(2), 437-441 (2013)
• [125] Y. G. Ma, G. V. Halade, J. H. Zhang, T. A. Ramirez, D. Levin, A. Voorhees, Y. F. Jin, H. C. Han, A. M. Manicone and M. L. Lindsey: Matrix Metalloproteinase-28 Deletion Exacerbates Cardiac Dysfunction and Rupture After Myocardial Infarction in Mice by Inhibiting M2 Macrophage Activation. Circ Res, 112(4), 675 (2013)
• [126] G. Poli, F. Biasi and G. Leonarduzzi: Oxysterols in the pathogenesis of major chronic diseases. Redox Biol, 1(1), 125-130 (2013)
• [127] Z. Li, Y. Guo, H. Jiang, T. Zhang, C. Jin, C. Y. Young and H. Yuan: Differential regulation of MMPs by E2F1, Sp1 and NF-kappa B controls the small cell lung cancer invasive phenotype. BMC Cancer, 14, 276 (2014)
• [128] R. A. Williamson, G. Martorell, M. D. Carr, G. Murphy, A. J. Docherty, R. B. Freedman and J. Feeney: Solution structure of the active domain of tissue inhibitor of metalloproteinases-2. A new member of the OB fold protein family. Biochemistry, 33(39), 11745-59 (1994)
• [129] K. Brew, D. Dinakarpandian and H. Nagase: Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta, 1477(1-2), 267-83 (2000)
• [130] R. Visse and H. Nagase: Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry_. Circ Res_, 92(8), 827-39 (2003)
• [131] H. Nagase, R. Visse and G. Murphy: Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res, 69(3), 562-73 (2006)
• [132] M. A. Lafleur, M. D. Hollenberg, S. J. Atkinson, K. V, G. Murphy and D. R. Edwards: Activation of pro-(matrix metalloproteinase-2) (pro-MMP-2) by thrombin is membrane-type-MMP-dependent in human umbilical vein endothelial cells and generates a distinct 63 kDa active species. Biochem J, 357, 107-115 (2001)
• [133] D. D. Li, J. N. Song, H. Huang, X. Y. Guo, J. Y. An, M. Zhang, Y. Li, P. Sun, H. G. Pang, Y. L. Zhao and J. F. Wang: The roles of MMP-9/TIMP-1 in cerebral edema following experimental acute cerebral infarction in rats. Neurosci Lett, 550, 168-72 (2013)
• [134] H. M. Xu, Y. Zhao, X. M. Zhang, T. Zhu and W. G. Fu: Polymorphisms in MMP-9 and TIMP-2 in Chinese patients with varicose veins. J Surg Res, 168(1), e143-8 (2011)
• [135] V. L. Andrade, E. Petruceli, V. A. Belo, C. M. Andrade-Fernandes, C. V. Caetano Russi, A. A. Bosco, J. E. Tanus-Santos and V. C. Sandrim: Evaluation of plasmatic MMP-8, MMP-9, TIMP-1 and MPO levels in obese and lean women. Clin Biochem, 45(6), 412-5 (2012)
• [136] Z. Li, S. Guo, F. Yao, Y. Zhang and T. Li: Increased ratio of serum matrix metalloproteinase-9 against TIMP-1 predicts poor wound healing in diabetic foot ulcers. J Diabetes Complications, 27(4), 380-2 (2013)
• [137] M. L. Lamfers, J. M. Grimbergen, M. C. Aalders, M. J. Havenga, M. R. de Vries, L. G. Huisman, V. W. van Hinsbergh and P. H. Quax: Gene transfer of the urokinase-type plasminogen activator receptor-targeted matrix metalloproteinase inhibitor TIMP-1.ATF suppresses neointima formation more efficiently than tissue inhibitor of metalloproteinase-1. Circ Res, 91(10), 945-52 (2002)
• [138] D. Eefting, M. R. de Vries, J. M. Grimbergen, J. C. Karper, J. H. van Bockel and P. H. Quax: In vivo suppression of vein graft disease by nonviral, electroporation-mediated, gene transfer of tissue inhibitor of metalloproteinase-1 linked to the amino terminal fragment of urokinase (TIMP-1.ATF), a cell-surface directed matrix metalloproteinase inhibitor. J Vasc Surg, 51(2), 429-37 (2010)
• [139] V. J. J. Cadete, S. A. Arcand, B. M. Chaharyn, A. Doroszko, J. Sawicka, D. D. Mousseau and G. Sawicki: Matrix Metalloproteinase-2 Is Activated During Ischemia/Reperfusion in a Model of Myocardial Infarction. Can J Cardiol, 29(11), 1495-1503 (2013)
• [140] C. K. Samadzadeh KM, Nguyen AT, Baker PM, Bains S, Lee ES.: Monocyte activity is linked with abdominal aortic aneurysm diameter. J Surg Res (2014)
• [141] C. L. Gao L, Lu ZZ, Gao H, Wu L, Chen YX, Zhang CM, Jiang YK, Jing Q, Zhang Y, Yang HT.: Activation of α1B-adrenoceptors contributes to intermittent hypobaric hypoxia-improved post-ischemic myocardial performance via inhibiting MMP-2 activation. Am J Physiol Heart Circ Physiol (2014)
• [142] C. R. Foster, L. L. Daniel, C. R. Daniels, S. Dalal, M. Singh and K. Singh: Deficiency of Ataxia Telangiectasia Mutated Kinase Modulates Cardiac Remodeling Following Myocardial Infarction: Involvement in Fibrosis and Apoptosis. PLoS One, 8(12) (2013)
• [143] N. Muradashvili, R. L. Benton, R. Tyagi, S. C. Tyagi and D. Lominadze: Elevated level of fibrinogen increases caveolae formation; role of matrix metalloproteinase-9. Cell Biochem Biophys, 69(2), 283-94 (2014)
• [144] H. Yao, J. W. Hwang, I. K. Sundar, A. E. Friedman, M. W. McBurney, L. Guarente, W. Gu, V. L. Kinnula and I. Rahman: SIRT1 redresses the imbalance of tissue inhibitor of matrix metalloproteinase-1 and matrix metalloproteinase-9 in the development of mouse emphysema and human COPD. Am J Physiol Lung Cell Mol Physiol, 305(9), L615-24 (2013)
• [145] E. C. El Hajj, M. C. El Hajj, T. G. Voloshenyuk, A. J. Mouton, E. Khoutorova, P. E. Molina, N. W. Gilpin and J. D. Gardner: Alcohol modulation of cardiac matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs favors collagen accumulation. Alcohol Clin Exp Res, 38(2), 448-56 (2014)
• [146] S. Udali, P. Guarini, S. Moruzzi, S. W. Choi and S. Friso: Cardiovascular epigenetics: from DNA methylation to microRNAs. Mol Aspects Med, 34(4), 883-901 (2013)
• [147] L. W. T. V. Shiva Shankar: Epigenetic modulators mitigate angiogenesis through a complex transcriptomic network. Vasc Pharmacol, 60, 57-66 (2014)
• [148] D. M. Hellebrekers, K. W. Jair, E. Vire, S. Eguchi, N. T. Hoebers, M. F. Fraga, M. Esteller, F. Fuks, S. B. Baylin, M. van Engeland and A. W. Griffioen: Angiostatic activity of DNA methyltransferase inhibitors. Mol Cancer Ther, 5(2), 467-75 (2006)
• [149] L. Ivanciu, R. D. Gerard, H. Tang, F. Lupu and C. Lupu: Adenovirus-mediated expression of tissue factor pathway inhibitor-2 inhibits endothelial cell migration and angiogenesis. Arterioscler Thromb Vasc Biol, 27(2), 310-6 (2007)
• [150] D. Miyazaki, A. Nakamura, K. Fukushima, K. Yoshida, S. Takeda and S. Ikeda: Matrix metalloproteinase-2 ablation in dystrophin-deficient mdx muscles reduces angiogenesis resulting in impaired growth of regenerated muscle fibers. Hum Mol Genet, 20(9), 1787-99 (2011)
• [151] C. Gupta, J. Kaur and K. Tikoo: Regulation of MDA-MB-231 cell proliferation by GSK-3beta involves epigenetic modifications under high glucose conditions. Exp Cell Res, 324(1), 75-83 (2014)
• [152] K. Sato-Kusubata, Y. Jiang, Y. Ueno and T. H. Chun: Adipogenic histone mark regulation by matrix metalloproteinase 14 in collagen-rich microenvironments. Mol Endocrinol, 25(5), 745-53 (2011)
• [153] M. Poplineau, J. Dufer, F. Antonicelli and A. Trussardi-Regnier: Epigenetic regulation of proMMP-1 expression in the HT1080 human fibrosarcoma cell line. Int J Oncol, 38(6), 1713-8 (2011)
• [154] R. A. Kowluru, J. M. Santos and M. Mishra: Epigenetic modifications and diabetic retinopathy. Biomed Res Int, 2013, 635284 (2013)
• [155] M. Osaki, A. Inaba, K. Nishikawa, Y. Sugimoto, K. Shomori, T. Inoue, M. Oshimura and H. Ito: Cysteine-rich protein 61 suppresses cell invasion via down-regulation of matrix metalloproteinase-7 expression in the human gastric carcinoma cell line MKN-45. Mol Med Rep, 3(4), 711-5 (2010)
• [156] N. Narayanan, N. Tyagi, A. Shah, S. Pagni and S. C. Tyagi: Hyperhomocysteinemia during aortic aneurysm, a plausible role of epigenetics. Int J Physiol Pathophysiol Pharmacol, 5(1), 32-42 (2013)
• [157] K. Chen and N. Rajewsky: The evolution of gene regulation by transcription factors and microRNAs. Nat Rev Genet, 8(2), 93-103 (2007)
• [158] K. C. Chen, Y. S. Wang, C. Y. Hu, W. C. Chang, Y. C. Liao, C. Y. Dai and S. H. Juo: OxLDL up-regulates microRNA-29b, leading to epigenetic modifications of MMP-2/MMP-9 genes: a novel mechanism for cardiovascular diseases. FASEB J, 25(5), 1718-28 (2011)
• [159] S. T. Boon RA, Heydt S, Fischer A, Hergenreider E, Horrevoets AJ, Vinciguerra M, Rosenthal N, Sciacca S, Pilato M, van Heijningen P, Essers J, Brandes RP, Zeiher AM, Dimmeler S.: Micro-RNA-29 in aortic dilation: implications for aneurysm formation. Circ Res 109(10), 1115-9 (2011)
• [160] K. C. Chen, Y. C. Liao, I. C. Hsieh, Y. S. Wang, C. Y. Hu and S. H. Juo: OxLDL causes both epigenetic modification and signaling regulation on the microRNA-29b gene: novel mechanisms for cardiovascular diseases. J Mol Cell Cardiol, 52(3), 587-95 (2012)
• [161] M. P. Turunen and S. Yla-Herttuala: Epigenetic regulation of key vascular genes and growth factors. Cardiovasc Res, 90(3), 441-446 (2011)
• [162] D. Wu, H. Pan, Y. Zhou, J. Zhou, Y. Fan and P. Qu: microRNA-133b downregulation and inhibition of cell proliferation, migration and invasion by targeting matrix metallopeptidase-9 in renal cell carcinoma. Mol Med Rep, 9(6), 2491-8 (2014)
• [163] X. Zhou, Y. Ren, A. Liu, L. Han, K. Zhang, S. Li, P. Li, C. Kang, X. Wang and L. Zhang: STAT3 inhibitor WP1066 attenuates miRNA-21 to suppress human oral squamous cell carcinoma growth in vitro and in vivo. Oncol Rep, 31(5), 2173-80 (2014)
• [164] Z. Ye, L. Jingzhong, L. Yangbo, C. Lei and Y. Jiandong: Propofol inhibits proliferation and invasion of osteosarcoma cells by regulation of microRNA-143 expression. Oncol Res, 21(4), 201-7 (2014)
• [165] P. Ye, J. Liu, F. He, W. Xu and K. Yao: Hypoxia-induced deregulation of miR-126 and its regulative effect on VEGF and MMP-9 expression. Int J Med Sci, 11(1), 17-23 (2014)
• [166] J. M. Siddesha, A. J. Valente, T. Yoshida, S. S. Sakamuri, P. Delafontaine, H. Iba, M. Noda and B. Chandrasekar: Docosahexaenoic acid reverses angiotensin II-induced RECK suppression and cardiac fibroblast migration. Cell Signal, 26(5), 933-41 (2014)
• [167] C. S. Palmieri D, Geroldi A, Mura M, Mandich P, Palombo D: TNFα induces the expression of genes associated with endothelial dysfunction through p38MAPK-mediated down-regulation of miR-149. Biochem Biophys Res Commun, 443(1), 246-51 (2014)
• [168] H. Y. Zhang, M. Qi, S. W. Li, T. Qi, H. Mei, K. Huang, L. D. Zheng and Q. S. Tong: microRNA-9 Targets Matrix Metalloproteinase 14 to Inhibit Invasion, Metastasis, and Angiogenesis of Neuroblastoma Cells. Mol Canc Ther, 11(7), 1454-1466 (2012)
• [169] V. Siragam, Z. J. Rutnam, W. Yang, L. Fang, L. Luo, X. Yang, M. Li, Z. Deng, J. Qian, C. Peng and B. B. Yang: MicroRNA miR-98 inhibits tumor angiogenesis and invasion by targeting activin receptor-like kinase-4 and matrix metalloproteinase-11. Oncotarget, 3(11), 1370-85 (2012)
• [170] R. Morales, S. Perrier, J. M. Florent, J. Beltra, S. Dufour, I. De Mendez, P. Manceau, A. Tertre, F. Moreau, D. Compere, A. C. Dublanchet and M. O’Gara: Crystal structures of novel non-peptidic, non-zinc chelating inhibitors bound to MMP-12. J Mol Biol, 341(4), 1063-76 (2004)
• [171] S. T. Huang, R. C. Yang, H. T. Wu, C. N. Wang and J. H. S. Pang: Zinc-Chelation Contributes to the Anti-Angiogenic Effect of Ellagic Acid on Inhibiting MMP-2 Activity, Cell Migration and Tube Formation. PLoS One, 6(5) (2011)
• [172] H. S. Rasmussen and P. P. McCann: Matrix metalloproteinase inhibition as a novel anticancer strategy: A review with special focus on batimastat and marimastat. Pharmacol Ther, 75(1), 69-75 (1997)
• [173] S. S. Kocer, S. G. Walker, B. Zerler, L. M. Golub and S. R. Simon: Metalloproteinase inhibitors, nonantimicrobial chemically modified tetracyclines, and ilomastat block Bacillus anthracis lethal factor activity in viable cells. Infect Immun, 73(11), 7548-57 (2005)
• [174] E. Koivunen, W. Arap, H. Valtanen, A. Rainisalo, O. P. Medina, P. Heikkila, C. Kantor, C. G. Gahmberg, T. Salo, Y. T. Konttinen, T. Sorsa, E. Ruoslahti and R. Pasqualini: Tumor targeting with a selective gelatinase inhibitor_. Nat Biotechnol_, 17(8), 768-74 (1999)
• [175] M. M. Castro, A. D. Kandasamy, N. Youssef and R. Schulz: Matrix metalloproteinase inhibitor properties of tetracyclines: therapeutic potential in cardiovascular diseases. Pharmacol Res, 64(6), 551-60 (2011)
• [176] Z. X. Luan, A. J. Chase and A. C. Newby: Statins inhibit secretion of metalloproteinases-1, -2, -3, and -9 from vascular smooth muscle cells and macrophages. Arterioscler Thromb Vasc Biol, 23(5), 769-775 (2003)
• [177] H. Mitani, K. Egashira and M. Kimura: HMG-CoA reductase inhibitor, fluvastatin, has cholesterol-lowering independent “direct” effects on atherosclerotic vessels in high cholesterol diet-fed rabbits. Pharmacol Res, 48(5), 417-427 (2003)
• [178] J. N. Freskos, B. Asmelash, K. R. Gaston, A. Karwa, T. A. Marzan, M. A. Nickols, T. E. Rogers, T. Schoenstein, C. J. Sympson and B. Vu: Design and synthesis of MMP inhibitors with appended fluorescent tags for imaging and visualization of matrix metalloproteinase enzymes. Bioorg Med Chem Lett, 23(20), 5566-5570 (2013)
• [179] S. Santamaria, E. Nuti, G. Cercignani, L. Marinelli, V. La Pietra, E. Novellino and A. Rossello: N-O-Isopropyl sulfonamido-based hydroxamates: Kinetic characterisation of a series of MMP-12/MMP-13 dual target inhibitors. Biochem Pharmacol, 84(6), 813-820 (2012)
• [180] V. La Pietra, L. Marinelli, S. Cosconati, F. S. Di Leva, E. Nuti, S. Santamaria, I. Pugliesi, M. Morelli, F. Casalini, A. Rossello, C. La Motta, S. Taliani, R. Visse, H. Nagase, F. da Settimo and E. Novellino: Identification of novel molecular scaffolds for the design of MMP-13 inhibitors: a first round of lead optimization. Eur J of Med Chem, 47(1), 143-52 (2012)
• [181] P. Jain, C. Saravanan and S. K. Singh: Sulphonamides: Deserving class as MMP inhibitors? Eur J Med Chem, 60, 89-100 (2013)
• [182] X. Xu, M. Mikhailova, Z. Chen, S. Pal, T. K. Robichaud, E. M. Lafer, S. Baber and B. Steffensen: Peptide from the C-terminal domain of tissue inhibitor of matrix metalloproteinases-2 (TIMP-2) inhibits membrane activation of matrix metalloproteinase-2 (MMP-2). Matrix Biol, 30(7-8), 404-12 (2011)
• [183] O. Nicolotti, M. Catto, I. Giangreco, M. Barletta, F. Leonetti, A. Stefanachi, L. Pisani, S. Cellamare, P. Tortorella, F. Loiodice and A. Carotti: Design, synthesis and biological evaluation of 5-hydroxy, 5-substituted-pyrimidine-2,4,6-triones as potent inhibitors of gelatinases MMP-2 and MMP-9. Eur J Med Chem, 58, 368-376 (2012)
• [184] A. Heim-Riether, S. J. Taylor, S. Liang, D. A. Gao, Z. Xiong, E. Michael August, B. K. Collins, B. T. Farmer, 2nd, K. Haverty, M. Hill-Drzewi, H. D. Junker, S. Mariana Margarit, N. Moss, T. Neumann, J. R. Proudfoot, L. S. Keenan, R. Sekul, Q. Zhang, J. Li and N. A. Farrow: Improving potency and selectivity of a new class of non-Zn-chelating MMP-13 inhibitors. Bioorg Med Chem Lett, 19(18), 5321-4 (2009)
• [185] D. A. Gao, Z. Xiong, A. Heim-Riether, L. Amodeo, E. M. August, X. Cao, L. Ciccarelli, B. K. Collins, K. Harrington, K. Haverty, M. Hill-Drzewi, X. Li, S. Liang, S. M. Margarit, N. Moss, N. Nagaraja, J. Proudfoot, R. Roman, S. Schlyer, L. S. Keenan, S. Taylor, B. Wellenzohn, D. Wiedenmayer, J. Li and N. A. Farrow: SAR studies of non-zinc-chelating MMP-13 inhibitors: improving selectivity and metabolic stability. Bioorg Med Chemi Lett, 20(17), 5039-43 (2010)
• [186] H. Yuan, W. Q. Lu, L. Y. Wang, L. Shan, H. L. Li, J. Huang, Q. Y. Sun and W. D. Zhang: Synthesis of derivatives of methyl rosmarinate and their inhibitory activities against matrix metalloproteinase-1 (MMP-1). Eur J Med Chem, 62, 148-157 (2013)
• [187] A. R. Farina, L. Cappabianca, N. Di Ianni, P. Ruggeri, M. Ragone, S. Merolle, A. Gulino and A. R. Mackay: Alendronate promotes plasmin-mediated MMP-9 inactivation by exposing cryptic plasmin degradation sites within the MMP-9 catalytic domain. FEBS Lett, 586(16), 2366-2374 (2012)
• [188] S. Y. Chuang, S. H. Yang, T. Y. Chen and J. H. S. Pang: Cilostazol inhibits matrix invasion and modulates the gene expressions of MMP-9 and TIMP-1 in PMA-differentiated THP-1 cells. Eur J Pharmacol, 670(2-3), 419-426 (2011)
• [189] M. Okada, R. Kikuzuki, T. Harada, Y. Hori, H. Yamawaki and Y. Hara: Captopril attenuates matrix metalloproteinase-2 and -9 in monocrotaline-induced right ventricular hypertrophy in rats. J Pharmacol Sci, 108(4), 487-94 (2008)
• [190] D. Yamamoto, S. Takai and M. Miyazaki: Inhibitory profiles of captopril on matrix metalloproteinase-9 activity. Eur J Pharmacol, 588(2-3), 277-9 (2008)
• [191] I. K. Onal, B. Altun, E. D. Onal, A. Kirkpantur, S. Gul Oz and C. Turgan: Serum levels of MMP-9 and TIMP-1 in primary hypertension and effect of antihypertensive treatment. Eur J Intern Med, 20(4), 369-72 (2009)
• [192] L. B. Kuntze, R. C. Antonio, T. C. Izidoro-Toledo, C. A. Meschiari, J. E. Tanus-Santos and R. F. Gerlach: Captopril and Lisinopril Only Inhibit Matrix Metalloproteinase-2 (MMP-2) Activity at Millimolar Concentrations. Basic Clin Pharmacol Toxicol, 114(3), 233-239 (2014)
• [193] J. P. Wang, Q. Zhang, X. H. Mei and X. Z. Zhang: Hydroxysafflor yellow A attenuates left ventricular remodeling after pressure overload-induced cardiac hypertrophy in rats. Pharmaceut Biol, 52(1), 31-35 (2014)
• [194] C. W. Lin, P. N. Chen, M. K. Chen, W. E. Yang, C. H. Tang, S. F. Yang and Y. S. Hsieh: Kaempferol Reduces Matrix Metalloproteinase-2 Expression by Down-Regulating ERK1/2 and the Activator Protein-1 Signaling Pathways in Oral Cancer Cells. PLoS One, 8(11) (2013)
• [195] P. K. Kamat, A. Kalani, S. Givvimani, P. B. Sathnur, S. C. Tyagi and N. Tyagi: Hydrogen Sulfide Attenuates Neurodegeneration and Neurovascular Dysfunction Induced by Intracerebral-Administered Homocysteine in Mice. Neuroscience, 252, 302-319 (2013)
• [196] U. Sen, C. Munjal, N. Qipshidze, O. Abe, R. Gargoum and S. C. Tyagi: Hydrogen sulfide regulates homocysteine-mediated glomerulosclerosis. Am J Nephrol, 31(5), 442-55 (2010)
• [197] U. Sen, P. Basu, O. A. Abe, S. Givvimani, N. Tyagi, N. Metreveli, K. S. Shah, J. C. Passmore and S. C. Tyagi: Hydrogen sulfide ameliorates hyperhomocysteinemia-associated chronic renal failure. Am J Physiol Renal Physiol, 297(2), F410-9 (2009)
• [198] B. Lavin, M. Gomez, O. M. Pello, B. Castejon, M. J. Piedras, M. Saura and C. Zaragoza: Nitric Oxide Prevents Aortic Neointimal Hyperplasia by Controlling Macrophage Polarization. Arterioscler Thromb Vasc Biol, 34(8), 1739-+ (2014)
• [199] S. Zucker, M. Drews, C. Conner, H. D. Foda, Y. A. DeClerck, K. E. Langley, W. F. Bahou, A. J. Docherty and J. Cao: Tissue inhibitor of metalloproteinase-2 (TIMP-2) binds to the catalytic domain of the cell surface receptor, membrane type 1-matrix metalloproteinase 1 (MT1-MMP). J Biol Chem, 273(2), 1216-22 (1998)
• [200] C. M. Overall, E. Tam, G. A. McQuibban, C. Morrison, U. M. Wallon, H. F. Bigg, A. E. King and C. R. Roberts: Domain interactions in the gelatinase A. TIMP-2.MT1-MMP activation complex. The ectodomain of the 44-kDa form of membrane type-1 matrix metalloproteinase does not modulate gelatinase A activation. J Biol Chem, 275(50), 39497-506 (2000)
• [201] H. S. Kai, G. S. Butler, C. J. Morrison, A. E. King, G. R. Pelman and C. M. Overall: Utilization of a novel recombinant myoglobin fusion protein expression system to characterize the tissue inhibitor of metalloproteinase (TIMP)-4 and TIMP-2 C-terminal domain and tails by mutagenesis. The importance of acidic residues in binding the MMP-2 hemopexin C-domain. J Biol Chem, 277(50), 48696-707 (2002)
• [202] G. Sawicki, V. Menon and B. I. Jugdutt: Improved balance between TIMP-3 and MMP-9 after regional myocardial ischemia-reperfusion during AT1 receptor blockade. J Card Fail, 10(5), 442-9 (2004)
• [203] T. Sakamoto and M. Seiki: Cytoplasmic tail of MT1-MMP regulates macrophage motility independently from its protease activity. Genes Cells, 14(5), 617-26 (2009)
• [204] I. Kazes, I. Elalamy, J. D. Sraer, M. Hatmi and G. Nguyen: Platelet release of trimolecular complex components MT1-MMP/TIMP2/MMP2: involvement in MMP2 activation and platelet aggregation. Blood, 96(9), 3064-9 (2000)
• [205] Z. Yin, A. A. Sada, O. M. Reslan, N. Narula and R. A. Khalil: Increased MMPs expression and decreased contraction in the rat myometrium during pregnancy and in response to prolonged stretch and sex hormones. Am J Physiol Endocrinol Metab, 303(1), E55-70 (2012)
• [206] V. E. de Meijer, D. Y. Sverdlov, Y. Popov, H. D. Le, J. A. Meisel, V. Nose, D. Schuppan and M. Puder: Broad-spectrum matrix metalloproteinase inhibition curbs inflammation and liver injury but aggravates experimental liver fibrosis in mice. PLoS One, 5(6), e11256 (2010)
• [207] P. Bencsik, J. Paloczi, G. F. Kocsis, J. Pipis, I. Belecz, Z. V. Varga, C. Csonka, A. Gorbe, T. Csont and P. Ferdinandy: Moderate inhibition of myocardial matrix metalloproteinase-2 by ilomastat is cardioprotective. Pharmacol Res: the official journal of the Italian Pharmacological Society, 80, 36-42 (2014)
• [208] X. Zhang, J. Bresee, G. B. Fields and W. B. Edwards: Near-infrared triple-helical peptide with quenched fluorophores for optical imaging of MMP-2 and MMP-9 proteolytic activity in vivo. Bioorg Med Chem Lett, 24(16), 3786-90 (2014)
• [209] Z. Luan, A. J. Chase and A. C. Newby: Statins inhibit secretion of metalloproteinases-1, -2, -3, and -9 from vascular smooth muscle cells and macrophages. Arterioscler Thromb Vasc Biol, 23(5), 769-75 (2003)
• [210] H. Nagashima, Y. Aoka, Y. Sakomura, A. Sakuta, S. Aomi, N. Ishizuka, N. Hagiwara, M. Kawana and H. Kasanuki: A 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, cerivastatin, suppresses production of matrix metalloproteinase-9 in human abdominal aortic aneurysm wall. J Vasc Surg, 36(1), 158-63 (2002)
• [211] L. Vincent, W. Chen, L. Hong, F. Mirshahi, Z. Mishal, T. Mirshahi-Khorassani, J. P. Vannier, J. Soria and C. Soria: Inhibition of endothelial cell migration by cerivastatin, an HMG-CoA reductase inhibitor: contribution to its anti-angiogenic effect. FEBS Lett, 495(3), 159-66 (2001)
• [212] Y. J. Chen and L. S. Chang: Simvastatin induces NFkappaB/p65 down-regulation and JNK1/c-Jun/ATF-2 activation, leading to matrix metalloproteinase-9 (MMP-9) but not MMP-2 down-regulation in human leukemia cells. Biochem Pharmacol, 92(4), 530-43 (2014)
• [213] K. A. Manu, M. K. Shanmugam, F. Li, L. Chen, K. S. Siveen, K. S. Ahn, A. P. Kumar and G. Sethi: Simvastatin sensitizes human gastric cancer xenograft in nude mice to capecitabine by suppressing nuclear factor-kappa B-regulated gene products. J Mol Med (Berl), 92(3), 267-76 (2014)
• [214] V. L. Andrade, I. B. do Valle and V. C. Sandrim: Simvastatin therapy decreases MMP-9 levels in obese women. J Clin Pharmacol, 53(10), 1072-7 (2013)
• [215] R. Janardhanan, B. Yang, P. Vohra, B. Roy, S. Withers, S. Bhattacharya, J. Mandrekar, H. Kong, E. B. Leof, D. Mukhopadhyay and S. Misra: Simvastatin reduces venous stenosis formation in a murine hemodialysis vascular access model. Kidney Int, 84(2), 338-52 (2013)
• [216] S. Kang, E. S. Kim and A. Moon: Simvastatin and lovastatin inhibit breast cell invasion induced by H-Ras. Oncol Rep, 21(5), 1317-22 (2009)
• [217] A. Slawinska-Brych, B. Zdzisinska and M. Kandefer-Szerszen: Fluvastatin inhibits growth and alters the malignant phenotype of the C6 glioma cell line. Pharmacol Rep, 66(1), 121-9 (2014)
• [218] H. Ozaki, Y. Miyashita, H. Watanabe and K. Shirai: Enhancement of MMP-9 activity in THP-1 cells by 7-ketocholesterol and its suppression by the HMG-CoA reductase inhibitor fluvastatin. J Atheroscler Thromb, 12(6), 308-14 (2005)
• [219] H. B. Leu, J. W. Chen, T. C. Wu, Y. A. Ding, S. J. Lin and M. J. Charng: Effects of fluvastatin, an HMG-CoA reductase inhibitor, on serum levels of interleukin-18 and matrix metalloproteinase-9 in patients with hypercholesterolemia. Clin Cardiol, 28(9), 423-8 (2005)
• [220] G. Pochetti, E. Gavuzzo, C. Campestre, M. Agamennone, P. Tortorella, V. Consalvi, C. Gallina, O. Hiller, H. Tschesche, P. A. Tucker and F. Mazza: Structural insight into the stereoselective inhibition of MMP-8 by enantiomeric sulfonamide phosphonates. J Med Chem, 49(3), 923-31 (2006)
• [221] D. P. Becker, C. I. Villamil, T. E. Barta, L. J. Bedell, T. L. Boehm, G. A. Decrescenzo, J. N. Freskos, D. P. Getman, S. Hockerman, R. Heintz, S. C. Howard, M. H. Li, J. J. McDonald, C. P. Carron, C. L. Funckes-Shippy, P. P. Mehta, G. E. Munie and C. A. Swearingen: Synthesis and structure-activity relationships of beta-and alpha-piperidine sulfone hydroxamic acid matrix metalloproteinase inhibitors with oral antitumor efficacy. J Med Chem, 48(21), 6713-30 (2005)
• [222] M. Mori, A. Massaro, V. Calderone, M. Fragai, C. Luchinat and A. Mordini: Discovery of a New Class of Potent MMP Inhibitors by Structure-Based Optimization of the Arylsulfonamide Scaffold. ACS Med Chem Lett, 4(6), 565-9 (2013)
• [223] H. Yuan, W. Lu, L. Wang, L. Shan, H. Li, J. Huang, Q. Sun and W. Zhang: Synthesis of derivatives of methyl rosmarinate and their inhibitory activities against matrix metalloproteinase-1 (MMP-1). Eur J Med Chem, 62, 148-57 (2013)
• [224] Y. Luo, L. Zhang, W. Y. Wang, Q. F. Hu, H. P. Song, Y. L. Su and Y. Z. Zhang: Alendronate retards the progression of lumbar intervertebral disc degeneration in ovariectomized rats. Bone, 55(2), 439-48 (2013)
• [225] Y. Omote, K. Deguchi, S. Kono, N. Liu, W. Liu, T. Kurata, T. Yamashita, Y. Ikeda and K. Abe: Neurovascular protection of cilostazol in stroke-prone spontaneous hypertensive rats associated with angiogenesis and pericyte proliferation. J Neurosci Res, 92(3), 369-74 (2014)
• [226] B. C. Yu, D. S. Lee, S. M. Bae, W. K. Jung, J. H. Chun, S. H. Urm, D. Y. Lee, S. J. Heo, S. G. Park, S. K. Seo, J. W. Yang, J. S. Choi, W. S. Park and I. W. Choi: The effect of cilostazol on the expression of matrix metalloproteinase-1 and type I procollagen in ultraviolet-irradiated human dermal fibroblasts. Life Sci, 92(4-5), 282-8 (2013)
• [227] M. Ishiguro, K. Mishiro, Y. Fujiwara, H. Chen, H. Izuta, K. Tsuruma, M. Shimazawa, S. Yoshimura, M. Satoh, T. Iwama and H. Hara: Phosphodiesterase-III inhibitor prevents hemorrhagic transformation induced by focal cerebral ischemia in mice treated with tPA. PLoS One, 5(12), e15178 (2010)
• [228] L. Devel, F. Beau, M. Amoura, L. Vera, E. Cassar-Lajeunesse, S. Garcia, B. Czarny, E. A. Stura and V. Dive: Simple pseudo-dipeptides with a P2’ glutamate: a novel inhibitor family of matrix metalloproteases and other metzincins. J Biol Chem, 287(32), 26647-56 (2012)
• [229] L. Devel, S. Garcia, B. Czarny, F. Beau, E. LaJeunesse, L. Vera, D. Georgiadis, E. Stura and V. Dive: Insights from selective non-phosphinic inhibitors of MMP-12 tailored to fit with an S1’ loop canonical conformation. J Biol Chem, 285(46), 35900-9 (2010)
• [230] J. Johnson, S. George, A. Newby, and C. Jackson. Divergent effects of matrix metalloproteinases 3,7, 9, 12 on atherosclerotic plaque stability in mouse brachiocephalic arteries. PNAS, 103(42), 15575-80 (2005)
• [231] L. Kevorkian, D. Young, C. Darrah, S. Donell, L. Shepstone, S. Porter, S. Brockbank, D. Edwards, A. Parker, I. Clark. Expression profiling of metalloproteinases and their inhibitors in cartilage. Arthritis Rheum, 50(1), 131-41 (2004)